E!1705 - GEN209 - Breakthrough biological treatment for triple negative breast cancer (TNBC) Genagon Therapeutics AB
| Reference number | |
| Coordinator | Region Uppsala - Akademiska sjukhuset Kliniken för allmän onkologi |
| Funding from Vinnova | SEK 1 357 189 |
| Project duration | September 2022 - August 2025 |
| Status | Completed |
| Venture | Eurostars |
Important results from the project
GEN209 achieved its main goals by identifying and verifying prognostic biomarkers for triple-negative breast cancer (TNBC) and developing predictive models for tissue and plasma. The project also strengthened collaborations, advanced methods for proteomics and statistical modeling, and laid the groundwork for future research and biomarker validation in TNBC.
Expected long term effects
The project is expected to improve long-term prognosis and risk assessment for TNBC patients through validated biomarkers and predictive models. It provides guidance for future drug development, strengthens research networks and expertise in proteomics and statistical modeling, and lays the foundation for continued research and potential clinical applications in TNBC.
Approach and implementation
The GEN209 project was structured around work packages focusing on biomarker identification and predictive modeling. Activities were relevant and aligned with project goals. The start was delayed by over six months due to legal clearance at Uppsala University Hospital, so active work for our part began in August 2024. Collaboration between partners worked well, and despite the delay, the project progressed according to plan.